Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

When Managing Low-Risk Patients With Chest Pain In The Emergency Department, Cardiac CT Is More Cost Effective
The use of cardiac CT for low-risk chest pain patients in the emergency department, instead of the traditional standard of care (SOC) workup, may reduce a patient"s length of stay and hospital charges, according to a study performed at the University of Washington School of Medicine, Seattle, WA. The SOC workup, which is timely and expensive, consists of a series of cardiac enzyme tests, ECGs and nuclear stress testing.
generic viagra online
Standard Chartered CFO Runs Blindfolded As Seeing Is Believing Becomes Official 2009 Standard Chartered Great City Race Beneficiary
Standard Chartered"s Group Finance Director, Richard Meddings, has pledged to run The Standard Chartered Great City Race 2009 blindfolded to help raise funds for the race"s official community partner, Seeing is Believing (SiB). Today, organisers call for the other runners to start fundraising and help make a difference*.
News of the day
Chlamydia Infection - The Most Commonly Reported Sexually Transmitted Infection In Europe - ECDC Issues Chlamydia Control Guidance
In the coming summer months it is estimated that 200,000 young people in Europe will become infected with Chlamydia and most of them won"t know that they are infected. Chlamydia trachomatis, the most common bacterial sexually transmitted infection in Europe, continues to increase in many countries. It affects mostly young adults under 25. The true occurrence of Chlamydia is most likely much higher than the official figures because the majority of the infected do not have clinical symptoms. Surveys in European countries have shown an estimated population prevalence of 5 to 10 % in young people.
Sexual Health

AltheaDx Receives CLIA Certification

AltheaDx, a world leader in the development of companion diagnostics and biopharma services, announced that they have successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. AltheaDx is offering high-quality patient and biopharma molecular testing services from their state-of-the-art, GMP, GLP, and now CLIA compliant facility located in the Sorrento Valley, San Diego. "We are excited about the addition of clinical laboratory testing to the suite of services in our offering," said David Macdonald, CEO of AltheaDx. "We are now able to extend our success into later stage clinical trials and provide broader market access for our assays. Our CLIA certification is an important milestone in realizing our strategy of bringing theranostics into clinical use." AltheaDx provides its customers with a full range of molecular biopharma services: from biomarker discovery, clinical studies, diagnostic translation, through to reporting clinical results. AltheaDx will immediately provide clinical genotyping services from their CLIA certified laboratory for the K-RAS gene, along with a menu of other high-value molecular tests. K-RAS testing allows clinicians to screen patients for mutations in the K-RAS gene, which are found in 35-45% of metastatic colorectal cancer cases as well as a variety of other cancers including breast, lung, and ovarian. K-RAS mutations have been shown to be predictive of limited clinical response and poor prognosis. Data announced at last year"s ASCO conference has led to a need for colorectal cancer patients to be screened for mutations in the K-RAS gene in order to identify the most appropriate therapy. Patients carrying mutations in the K-RAS gene do not respond to a class of drugs known as EGFR inhibitors -- such as Vectibix® and Erbitux®. AltheaDx


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009